Anastrozole Treatment Duration for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer

Standard Treatment Duration

The standard duration of anastrozole treatment is 5 years for adjuvant treatment of early breast cancer in postmenopausal women, as recommended by the American College of Clinical Oncology, with anastrozole 1 mg daily for 5 years significantly reducing breast cancer incidence compared to placebo in high-risk postmenopausal women 2, 3

Node-positive patients derive the most substantial benefit from extended therapy and should be offered treatment up to 10 years total, as recommended by the American Society of Clinical Oncology, with a 34% relative risk reduction in disease recurrence 1, 4
Higher-risk node-negative disease patients should consider extension based on established prognostic factors, including young age and high-grade tumors, as recommended by the National Comprehensive Cancer Network 1, 4

Women should receive no more than 10 years of total endocrine treatment, as recommended by the American College of Clinical Oncology, with no evidence supporting benefit beyond 10 years and toxicity accumulating over time 1, 4

Extended anastrozole therapy provides a reduced distant recurrence risk, with a 34% relative risk reduction in disease recurrence, as reported by the American Society of Clinical Oncology 4
Extended anastrozole therapy also provides prevention of contralateral breast cancer, with a 58% relative risk reduction in new opposite-breast cancers, as reported by the American Society of Clinical Oncology 4
However, extended therapy does not improve overall survival, only prevents recurrence and second cancers, as recommended by the American College of Clinical Oncology 1, 4

The decision to extend therapy must weigh significant adverse effects, including bone-related events, such as increased fractures and new osteoporosis, as reported by the American Society of Clinical Oncology 4
Cardiovascular events, such as trend toward increased risk, should also be considered, as reported by the American College of Clinical Oncology 1, 4
Musculoskeletal symptoms, such as joint stiffness and arthralgia, are common, as reported by the Journal of Clinical Oncology 3, 5

Women with severe osteoporosis should consider alternative therapies, such as tamoxifen or raloxifene, as recommended by the Journal of Clinical Oncology 3
Patients receiving anastrozole should be encouraged to exercise regularly and take adequate calcium and vitamin D supplements, as recommended by the Journal of Clinical Oncology 3

For postmenopausal women at high risk without breast cancer, anastrozole 1 mg daily for 5 years reduces invasive and noninvasive breast cancer incidence, as reported by the Journal of Clinical Oncology 2, 3
For postmenopausal women with ER-positive DCIS, anastrozole provides comparable benefit to tamoxifen with a different toxicity profile, as reported by the Journal of the National Comprehensive Cancer Network 6